Melatonin Metabolism Abnormality in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2024

Conditions
SchizophreniaSchizoaffective DisorderBipolar DisorderObesityMetabolic Syndrome
Interventions
DRUG

olanzapine and melatonin

In treatment phase I, all subjects will receive olanzapine, 10-25 mg/day. In treatment phase II, all subjects will receive olanzapine (10-25 mg/day) plus melatonin. Subjects will be randomized at a ratio of 1:1 to receive melatonin, 0.3 mg/day or 3.0 mg/day. Group IIA will receive 0.3mg day melatonin. Group IIB will receive 3.0 mg/day melatonin.

Trial Locations (1)

98493

VA Puget Sound Health Care System, Tacoma

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Seattle Institute for Biomedical and Clinical Research

OTHER

NCT00512070 - Melatonin Metabolism Abnormality in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine | Biotech Hunter | Biotech Hunter